Science News

A rash of new anti-HIV drugs

Sun, 5th Aug 2007

Listen Now    Download as mp3 from the show Venoms and Toxins - Nature's Chemical Arsenal

A cluster of new anti-AIDS drugs are expected to be approved for general use later this year, giving hope to patients who have developed drug-resistant forms of the virus. This is because the new agents hit different parts of the virus compared with existing anti-HIV drugs, which means that there should be very little initial drug-resistance. The new agents include two "fusion inhibitors", maraviroc, made by Pfizer, and vicrivoroc, which has been developed by Schering Plough. These drugs block the ability of HIV to lock onto a molecule on the cell surface called CCR5, which the virus needs in order to penetrate and infect. The other agent, raltegravir, is made by Merck. It locks onto a viral protein called integrase and prevents it from inserting a copy of its genetic material into the host DNA, which is a critical step in the viral lifecycle. When both of these approaches have been combined (a fusion inhibitor given together with the integrase inhibitor), in patients with drug-resistant disease, the viral load in the bloodstream fell to undetectable levels, indicating good disease control.

Multimedia

Subscribe Free

Related Content

Not working please enable javascript
EPSRC
Powered by UKfast
STFC
Genetics Society
ipDTL